AVEO - AVEO Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

2.225

+0.275 (+14.10%)

As of 3:35PM EDT. Market open.

Stock chart is not supported by your current browser

Previous Close	1.950
Open	2.100
Bid	2.210 x 4000
Ask	2.220 x 800
Day's Range	1.990 - 2.250
52 Week Range	1.860 - 4.240
Volume	7,085,211
Avg. Volume	2,124,869

Market Cap	343.26M
Beta	1.18
PE Ratio (TTM)	N/A
EPS (TTM)	-0.559
Earnings Date	May 11, 2017 - May 12, 2017
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	5.67

Trade prices are not sourced from all markets

All

News

Press Releases

Business Wire9 hours ago
AVEO Oncology Issues Statement Regarding Revised TIVO-3 Trial Guidance
AVEO Oncology (AVEO) today issued the following statement regarding its recently revised guidance on the timing of topline data from the TIVO-3 study, its Phase 3 trial of tivozanib as a third-line treatment for advanced renal cell carcinoma. “The Company expects to report topline results from the TIVO-3 study in the fourth quarter of 2018, approximately 6-8 weeks after the trial records 255 progression free survival (PFS) events. The one-time adjustment in the event count is the result of an administrative error that occurred from counting, as PFS events, the deaths of ten patients who had left the study without documented radiographic progression.
Market Realistyesterday
Aveo Pharmaceuticals’ Stock Plunged around 24.2% Yesterday
Yesterday, Aveo Pharmaceuticals (AVEO) issued an 8-K filing reporting its plan to release top-line data from its Phase 3 trial TIVO-3 in Q4 2018. In the US Phase 3 registrational study, the company is examining the vascular endothelial growth factor receptor (or VEGFR) 123 tyrosine kinase inhibitor (or TKI) Fotivda (tivozanib) for third-line advanced renal cell carcinoma (or RCC).
ACCESSWIREyesterday
Today's Research Reports on Stocks to Watch: AVEO Pharmaceuticals and ACADIA Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / July 18, 2018 / Shares of AVEO Pharmaceuticals were deep in the red on Tuesday after a SEC 8-K revealed that the company’s TIVO-3 data is now delayed until the fourth quarter. Shares of ACADIA Pharmaceuticals were in the green despite any news. AVEO Pharmaceuticals, Inc. shares closed down 24.21% on Tuesday with nearly 9.4 million shares traded.
GlobeNewswire23 days ago
Research Report Identifies Six Flags Entertainment Corporation New, AVEO Pharmaceuticals, Chipotle Mexican Grill, NGL Energy Partners LP, DSW, and GoDaddy with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, June 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Six ...
ACCESSWIRE24 days ago
Free Pre-Market Technical Pulse on AVEO Pharma and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on AVEO sign up now at www.wallstequities.com/registration. Last Friday, shares in Cambridge, Massachusetts-based AVEO Pharmaceuticals Inc. ended the session 4.35% higher at $2.40.
Business Wire24 days ago
AVEO Oncology Added to the Russell 2000, Russell 3000, and Russell Microcap Indexes
AVEO Oncology (AVEO) today announced that it has been added to the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes, effective after the U.S. market closed on Friday, June 22, 2018 as part of FTSE’s annual reconstitution. “We believe that inclusion in the widely referenced Russell U.S. Indexes reflects the significant progress we have made as a Company in the last year, including European approval of tivozanib for the treatment of adult patients with advanced kidney cancer,” said Michael Bailey, president and chief executive officer of AVEO. Annual Russell U.S. Indexes reconstitution captures the 4,000 largest US stocks as of May 11, ranking them by total market capitalization.
Zackslast month
Do Options Traders Know Something About AVEO Pharmaceuticals (AVEO) Stock We Don't?
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
Zackslast month
Why Is AVEO Pharmaceuticals (AVEO) Down 1.6% Since Its Last Earnings Report?
AVEO Pharmaceuticals (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Business Wire2 months ago
AVEO Oncology to Present at the Jefferies 2018 Healthcare Conference
AVEO Oncology (AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Jefferies 2018 Healthcare Conference in New York on Thursday, June 7, 2018 at 9:30 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need.
ACCESSWIRE2 months ago
Audentes Therapeutics and Three More Stocks Under Scanner in the Biotech Space
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want a free Stock Review on AVEO, CLDX, and CERS sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Audentes Therapeutics Inc. (NASDAQ: BOLD), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Cerus Corp. (NASDAQ: CERS).
Zacks2 months ago
AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the first quarter while revenues come almost in-line with estimates. Data from TIVO-3 study postponed. Shares down.
GlobeNewswire2 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within F.N.B., Comcast, IZEA, AVEO Pharmaceuticals, Matador Resources, and TEGNA — New Research Emphasizes Economic Growth
NEW YORK, May 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of F.N.B. ...
Market Exclusive2 months ago
Here Is What Just Happened With Aveo Pharmaceuticals
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is attracting a substantial amount of attention in the biotechnology space early morning out of Europe this week, with the company moving on and update related to one of its lead development assets in the sector. Here is a look at what happened and why it is important for AVEO and […] The post Here Is What Just Happened With Aveo Pharmaceuticals appeared first on Market Exclusive.
Motley Fool2 months ago
Here's Why AVEO Pharmaceuticals Fell as Much as 17% Today
The company announced a delay concerning its top drug candidate.
Business Wire2 months ago
AVEO Reports First Quarter 2018 Financial Results and Provides Business Update
AVEO Oncology today reported financial results for the first quarter ended March 31, 2018 and provided a business update.
Zacks3 months ago
AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?
AVEO Pharmaceuticals' (AVEO) first drug, Fotivda for the first-line treatment of RCC is likely to have a favorable impact on first-quarter results.
Zacks3 months ago
Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
Surging implied volatility makes AVEO Pharmaceuticals (AVEO) lucrative to the option traders.
Zacks3 months ago
AVEO Down 7.7% Since Earnings Report: Can It Rebound?
AVEO reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Motley Fool3 months ago
Why AVEO Oncology Jumped Higher Today
Investors see value after last week's decline.
ACCESSWIRE3 months ago
Today’s Research Reports on Trending Tickers: AVEO Pharmaceuticals and Neovasc
NEW YORK, NY / ACCESSWIRE / April 6, 2018 / U.S. markets ended higher on Thursday for their third straight daily gain as technology stocks recover from a series of shortcomings. The Dow Jones Industrial ...
Zacks3 months ago
Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)
Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)
Business Wire4 months ago
AVEO Oncology to Present at Upcoming Conferences
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences:
Zacks4 months ago
Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
AVEO Pharmaceuticals (AVEO) needs investors to pay close attention to the stock based on moves in the options market lately.
Business Wire4 months ago
AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC
AVEO Oncology today announced the publication of long-term follow-up results from Study 902, where patients were treated with tivozanib as second-line treatment in advanced renal cell carcinoma , in the European Journal of Cancer.
Zacks4 months ago
AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the fourth quarter with revenues missing estimates. The top line also declines year over year.